Pharmacyclics’ Xcytrin Gets FDA “Not Approvable” For NSCLC Patients With Brain Metastases
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Richard Miller calls for FDA to release the “biotech bottleneck” caused by its approvals process.